Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment

References

[1] Ahmed N, Brawley VS, Hegde M (2015) Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol 33(15):1688–1696

[2] Dredge K, Marriott JB, Todryk SM, Dalgleish AG (2015) Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 51(10):521–531

[3] Gao H, Li K, Tu H (2014) Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 20(24):6418–6428

[4] Gilham DE, Debets R, Pule M, Hawkins RE, Abken H (2012) CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 18(7):377–384

[5] Grupp SA, Kalos M, Barrett D (2013) Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med 368 (16):1509–1518

[6] Kalos M, Levine BL, Porter DL (2011) Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73

[7] Kohler BA, Sherman RL, Howlader N, (2015) Annual Report to the Nation on the Status of Cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107(6)

[8] Li W, Guo L, Rathi P,Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S,Metelitsa LS,Heczey A (2016) Redirecting T Cells toGlypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther2016 Aug 16

[9] Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y (2015) The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367 (2):103–107

[10] Maude SL, Frey N, Shaw PA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (16):1507–1517

[11] Pule MA, Savoldo B,Myers GD (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence andantitumor activity in individuals with neuroblastoma. Nat Med 14 (11):1264–1270

[12] Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo M, Selvan S (2011) Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 51(2–3):170–182

[13] Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ (1996) T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 97(8):1931–1941

[14] Zhao Zeguo, Condomines Maud, van der Stegen Sjoukje JC, Perna Fabiana, Kloss Christopher C, Gunset Gertrude, Plotkin Jason, Sadelain Michel (2015) Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell 28:415–428

[15] Zhu AX, Gold PJ, El-Khoueiry AB (2013) First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 19(4):920–928

RIGHTS & PERMISSIONS

2017 The Author(s) 2017. This article is an open access publication